CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
Rabeprazole 20 mg twice a day for 90-day period treatmentdrug
Likely dose
Rabeprazole 20 mg twice a day for 90-day period treatmentfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00199953
NCT00199953Phase 2Completed
CompareCT.gov

Post-nasal Drainage as an Extraesophageal Manifestation of Reflux

Medical College of Wisconsin·interventional·Posted Sep 20, 2005·Updated Jan 30, 2017

In Brief

A Phase 2 clinical trial evaluating Rabeprazole 20 mg twice a day for 90-day period treatment for Postnasal Drainage. Completed, across 1 site.

Detailed Summary

Objectives of this study are: * To quantitatively evaluate the relationship between extraesophageal manifestations of gastroesophageal reflux (EER) and postnasal drainage(PND)in a group of patients without radiographic or endoscopic evidence of sinonasal inflammatory disease. * To assess the efficacy of BID proton pump inhibitors (PPI) in the management of patients with symptomatic postnasal drainage.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostnasal Drainage
CountriesUnited States
CollaboratorsOrtho-McNeil, Inc., Eisai Inc.

Timeline

Phase 2CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 20, 2005
Enrollment StartJun 1, 2002
Primary CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 20.8 years ago

Interventions

Rabeprazole 20 mg twice a day for 90-day period treatmentdrug